SHL Group has announced it will hold a live webinar to discuss how pharmaceutical companies can leverage a preconfigured device technology to bring their innovative drug formulations to market more efficiently.
Taking place on 22 March at 3:00pm (London) / 10:00am (New York), the webinar is titled ‘The Faster Path to Market: How Pharma Can Benefit from Using a Robust and Well-Defined Preconfigured Drug Delivery Device’. It will be led by Dr Thomas P Schönknecht, executive director of business development at SHL Group.
With the increase in chronic diseases and the emergence of biological and biosimilar drug formulations, self-injection devices have continued to see strong and consistent growth. More and more pharmaceutical companies are thereby leveraging preconfigured offerings to increase efficiency, reduce costs and ultimately shorten time-to-market for their novel therapies.
In the webinar, Dr Schönknecht will address this trend while exploring the challenges, opportunities and key traits of a successful preconfigured device. He will also look at the regulatory considerations that are required in order to support the approval, as well as entire life-cycle of the drug product.
About the speaker Thomas Schönknecht
Thomas Schönknecht is an executive director for business development at SHL Group. He has more than 20 years’ experience in the pharmaceutical industry, working in various leading roles, including project management, research and development (R&D), and business development for advanced drug delivery solutions.
Dr Schönknecht holds a PhD in biophysical chemistry from the Max-Planck-Society and the University Goettingen, Germany, as well as a master’s degree in chemistry from the University Goettingen. He is a frequent speaker, moderator and committee member at conferences regarding drug delivery and packing material science.
Key learning objectives and audience
The key learning objectives of the webinar will be:
- Core elements of a device programme
- Benefits of a preconfigured technology
- Aligning your innovation with regulatory strategies
- Vital traits of a successful preconfigured device
The main target audiences include:
- Device and packaging development
- Product development
- New product introduction
- Clinical supply chain
- Process development
- Business development
- Device strategy
- Technical development
- Commercial operations
- Research and innovation
Register to join Dr. Schönknecht and learn more about how to turn an innovative drug into a winning combination product.